John Magenau is a Hematology physician affiliated with University of Michigan. OpenAlex indexes 157 publications with 7,520 citations (h-index 30); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 23 Nov 2020.
Clinical trials
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sponsor: University of Michigan Rogel Cancer Center
- Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Sponsor: University of Michigan Rogel Cancer Center
- Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year20216 payments
- Gilead Sciences, Inc.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
28.8%Corticosteroid20.1%Prednisone100%Part D<11 patientsProton pump inhibitor8.6%Omeprazole100%Part D<11 patientsDermatology
21.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.6%Acyclovir100%Part D<11 patientsSensory organs
18.7%Corticosteroid18.7%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2017–2021 per NIH RePORTER. The latest:
- Targeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantation
University of Michigan at Ann Arbor
FY2021$196,560K23AI123595 - Targeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantation
University of Michigan at Ann Arbor
FY2020$196,560K23AI123595 - Targeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantation
University of Michigan at Ann Arbor
FY2019$196,560K23AI123595
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score
Journal of the American Heart Association
2023 - NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Journal of the National Comprehensive Cancer Network
2023 - Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes
Biology of Blood and Marrow Transplantation
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”